학술논문
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Document Type
Article
Author
Hilbrandt, Moritz; Süptitz, Juliane; Grah, Christian; Velthaus, Janna-Lisa; Kopp, Hans-Georg; Schmidt, Bernd; Horter, Susanne; Keymel, Stefanie; Aydilek, Enver; Tritchkova, Guergana; Raspe, Matthias; Papić, Dražen; Florian, Stefan; Horst, David; Wild, Peter J.; Thomas, Michael; Grohé, Christian; Bleckmann, Annalen; Wermke, Martin; Hummel, Horst-Dieter; Stratmann, Jan; Schütte, Wolfgang; Bischoff, Philip; Reck, Martin; Overbeck, Tobias; Christopoulos, Petros; Rittmeyer, Achim; Lüders, Heike; Kollmeier, Jens; Kulhavy, Jonas; Kemper, Marcel; Reinmuth, Niels; Röper, Julia; Janning, Melanie; Sommer, Linna; Aguinarte, Lukas; Koch, Myriam; Wiesweg, Marcel; Wesseler, Claas; Waller, Cornelius F.; Kauffmann-Guerrero, Diego; Stenzinger, Albrecht; Stephan-Falkenau, Susann; Trautmann, Marcel; Lassmann, Silke; Tiemann, Markus; Klauschen, Frederick; Sebastian, Martin; Griesinger, Frank; Wolf, Jürgen; Loges, Sonja; Frost, Nikolaj
Source
In Journal of Thoracic Oncology May 2024 19(5):803-817
Subject
Language
ISSN
1556-0864